| 摘要: | 摘要: 目的 运用循证医学Meta分析方法,探究和评价新型冠状病毒疫苗对新型冠状病毒德尔塔变异株的预防效果,为新冠肺炎的防控提供循证支持。方法 以新型冠状病毒德尔塔毒株、疫苗及其同义词、近义词作为检索词,系统检索中国知网、万方数据库、维普数据库、中国生物医学文献服务系统、PubMed、考科蓝图书馆、Web of Science、BioRxiv、MedRxiv和Europe PMC关于新型冠状病毒疫苗保护效果(Vaccine Effectiveness,VE)的文献,使用纽卡斯尔-渥太华风险评分量表对纳入的队列研究和病例对照研究文献进行质量评价,对纳入的随机对照试验则使用Jadad评分进行质量评价,运用Stata 12.0进行异质性检验、总效应值和发表性偏倚估计。结果 共纳入文献14篇,其中病例对照研究文献5篇,队列研究文献8篇,随机对照实验1篇。Meta分析显示,接种一剂新冠疫苗的合并VE(95%CI)为34.57%(95%CI:21.70%～47.44%),接种两剂新型冠状病毒疫苗的合并VE(95%CI)为70.56%(95%CI: 64.29%～76.82%)。漏斗图分析表明存在发表偏倚风险。结论 接种新型冠状病毒疫苗对预防新型冠状病毒德尔塔变异株有保护作用,且2剂疫苗保护作用明显比1剂疫苗强。后续仍需要收集更多的疫苗保护率研究,提供发表性偏倚风险小的证据。 |
|---|
| Abstract: | Abstract: Objective To estimate the vaccine effectiveness(VE)for infection and provide evidence-based support for prevention and control with delta variants of SARS-CoV-2. Methods Delta variants of SARS-CoV-2, vaccine and their synonyms were used as the retrieval terms, and systematic retrieval was performed in CNKI, Wanfang Data knowledge service platform, Weipu database, SinoMed, PubMed, Cochrane Library, Web of Science, BioRxiv, MedRxiv and Europe PMC literature on the effectiveness of vaccines for infection with delta variants of SARS-CoV-2. The Newcastle Ottawa scale(NOS)was used to assess the quality of the included cohort studies and case-control studies, the Jadad scale was used to assess the quality of randomized controlled trials, and Stata 12.0 was used to test the heterogeneity, total effect value and publication bias. Results a total of 14 papers were included, including 5 case-control studies, 8 cohort studies, and 1 randomized controlled trial. Meta analysis showed that the pooled VE(95%CI)was 34.57%(95%CI: 21.70%- 47.44%)for one dose and 70.56%(95%CI: 64.29%- 76.82%)for two doses of the vaccine. Funnel plot indicated that there was a risk of publication bias. Conclusion The vaccine for infection with delta variants of SARS-CoV-2 is effective. The effectiveness of two doses of vaccine is stronger than that of the one dose. It is necessary to collect more studies in future on vaccine effectiveness to provide stronger evidence with low risk of publication bias. |
|---|
参考文献
/References:
| 参考文献
/References: [1] Wiersinga WJ, Rhodes A, Cheng AC, et al. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019(COVID-19): A review[J]. JAMA, 2020, 324(8): 782-793.
[2] 李雯.已扩至92个国家,该如何防范[N].新华每日电讯,2021-06-23(012).Li W. "Delta" has spread to 92 countries, how to prevent it[N]. Xinhua Daily Telegraph, 2021-06-23(012).
[3] 佚名.德尔塔变异株有哪些特点?[J].新疆农垦科技,2021,44(4):70.Anon. What are the characteristics of delta variants of SARS-CoV-2?[J]. Xinjiang Farm Research of Science and Technology, 2021, 44(4): 70.
[4] 刘畅,陈颖安,赵双雨,等.新型冠状病毒肺炎疫苗安全性的Meta分析[J].中国循证医学杂志,2021,21(6):676-682.Liu C, Chen YA, Zhao SY, et al. Safety of COVID-19 vaccine: a meta-analysis[J]. Chinese Journal of Evidence-Based Medicine, 2021, 21(6): 676-682.
[5] Lo CK, Mertz D, Loeb M. Newcastle-Ottawa scale: comparing reviewers’ to authors’ assessments[J]. BMC Medical Research Methodology, 2014, 14(1): 45.
[6] Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of covid-19 vaccines against the B.1.617.2(delta)variant[J]. The New England Journal of Medicine, 2021, 385(7): 585-594.
[7] SeppääE, Veneti L, Starrfelt J, et al. Vaccine effectiveness against infection with the Delta(B.1.617.2)variant, Norway, April to August 2021[J]. European Communicable Disease Bulletin, 2021, 26(35): 2100793.
[8] Li XN, Huang Y, Wang W, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study[J]. Emerging Microbes & Infections, 2021, 10(1): 1751-1759.
[9] Kang M, Yi Y, Li Y, et al. Effectiveness of inactivated COVID-19 vaccines against COVID-19 pneumonia and severe illness caused by the B[EB/OL].
[2022-07-21]. http://dx.doi.org/10.2139.
[10] Tang P, Hasan MR, Chemaitelly H, et al. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the Delta(B.1.617.2)variant in Qatar[EB/OL].
[2022-07-20]. https://www.medrxiv.org/content/10.1101/2021.08.11.21261885v1.
[11] Pouwels KB, Pritchard E, Matthews PC, et al. Impact of delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK[EB/OL].
[2022-07-20]. https://www.medrxiv.org/content/10.1101/2021.08.18.21262237v1.
[12] Satwik R, Satwik A, Katoch S, et al. ChAdOx1 nCoV-19 effectiveness during an unprecedented surge in SARS COV-2 infections[J]. European Journal of Internal Medicine, 2021, 93(21): 112-113.
[13] Nasreen S, He S, Chung H, et al. Effectiveness of COVID-19 vaccines against variants of concern, Canada[J]. BMJ(Online), 2021, 374: n1943.
[14] Fowlkes A, Gaglani M, Groover K, et al. Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection among frontline workers before and during B.1.617.2(delta)variant predominance - eight U.S. locations, December 2020-August 2021[J]. MMWR. Morbidity and Mortality Weekly Report, 2021, 70(34): 1167-1169.
[15] Nanduri S, Pilishvili T, Derado G, et al. Effectiveness of Pfizer-BioNTech and moderna vaccines in preventing SARS-CoV-2 infection among nursing home residents before and during widespread circulation of the SARS-CoV-2 B.1.617.2(delta)Variant-National healthcare safety network,March 1-August 1,2021[J]. MMWR. Morbidity and Mortality Weekly Report, 2021, 70(34): 1163-1166.
[16] Sheikh A, Mcmenamin J, Taylor B, et al. SARS-CoV-2 delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness[J]. Lancet(London, England), 2021, 397(1293): 2461-2462.
[17] Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine(BBV152): a, double-blind, randomised, controlled phase 3 trial[EB/OL].
[2022-07-20]. https://www.medrxiv.org/content/10.1101/2021.06.30.21259439v1.full.pdf.
[18] Puranik A, Lenehan P, Silvert E, et al. Comparison of two Highly-Effective mRNA vaccines for COVID-19 during periods of alpha and delta variant prevalence[EB/OL].
[2022-07-20]. https://pubmed.ncbi.nlm.nih.gov/34401884/.
[19] Andrews N, Tessier E, Stowe J, et al. Vaccine effectiveness and duration of protection of Comirnaty,Vaxzevria and Spikevax against mild and severe COVID-19 in the UK[EB/OL].
[2022-07-20]. https://www.medrxiv.org/content/10.1101/2021.09.15.21263583v1.
[20] World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020[EB/OL].
[2022-07-20]. https://www.who.int/zh/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
[21] 澎湃网.两个国产新冠疫苗同时获附条件上市,国内已上市4款新冠疫苗[EB/OL].
[2022-07-25]. https://www.thepaper.cn/newsDetail_forward_11461048.Peng PW. Two domestically-made COVID-19 vaccines are listed at the same time with conditions, and 4 COVID-19 vaccines have been marketed in China[EB/OL].
[2022-07-25]. https://www.thepaper.cn/newsDetail_forward_11461048.
[22] 新华网.更广泛的疫苗接种有助于我国建立免疫屏障[EB/OL].
[2022-07-21]. http://www.news.cn/english/2021-11/03/c_1310287699.htm.Xinhuanet. Wider vaccination helps China build immune barrier against coronavirus[EB/OL].
[2022-07-21]. http://www.news.cn/english/2021-11/03/c_1310287699.htm.
[23] 杨朝国,刘继芬,蒋宏.COVID-19疫苗免疫应答及保护效力研究进展[J].中国公共卫生,2021,37(5):896-901.Yang CG, Liu JF, Jiang H.Progress in research on immune responses and protective efficacy elicited by COVID-19 vaccine[J]. Chinese Journal of Public Health, 2021, 37(5): 896-901.
[24] 世界卫生组织.世卫组织工作组–2019冠状病毒病疫苗目标产品概况[EB/OL].
[2020-07-20].https://www.who.int/publications/m/item/who-working-group-target-product-profiles-for-covid-19-vaccines.World Health Organization. WHO Working Group– Target Product Profiles for COVID-19Vaccines[EB/OL].
[2020-07-20]. https://www.who.int/publications/m/item/who-working-group-target-product-profiles-for-covid-19-vaccines.
[25] 中华人民共和国国家健康委员会.我国新冠疫苗接种人数达11亿 超10亿人完成全程接种[EB/OL].
[2022-07-21].http://www.nhc.gov.cn/xcs/yqfkdt/202109/bf2cf785ce0544ae818a76ffbb18ca79.shtml.National Health Commission of the People’s Republic ofChina. The number of people vaccinated against COVID-19 in China reaches 1.1 billion, and more than 1 billion people have completed the whole process[EB/OL].
[2022-07-21]. http://www.nhc.gov.cn/xcs/yqfkdt/202109/bf2cf785ce0544ae818a76ffbb18ca79.shtml.
|
|---|
